Compare JYNT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | ARMP |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.5M | 125.7M |
| IPO Year | 2014 | N/A |
| Metric | JYNT | ARMP |
|---|---|---|
| Price | $9.02 | $5.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.00 | $9.00 |
| AVG Volume (30 Days) | ★ 157.5K | 80.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,176,002.00 | $5,054,000.00 |
| Revenue This Year | $6.11 | $4.48 |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.47 | N/A |
| 52 Week Low | $7.50 | $0.90 |
| 52 Week High | $13.47 | $16.34 |
| Indicator | JYNT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 66.14 | 46.55 |
| Support Level | $8.06 | $5.49 |
| Resistance Level | $8.53 | $6.18 |
| Average True Range (ATR) | 0.28 | 0.58 |
| MACD | 0.08 | -0.23 |
| Stochastic Oscillator | 97.96 | 20.59 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.